PLX Stock Analysis: Buy, Sell, or Hold?
PLX - Protalix BioTherapeutics, Inc. Common Stock
$2.37
-0.01 (-0.63%)
âŧ
5d:
+3.28%
30d:
-0.21%
90d:
+12.62%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 12, 2026
0d
Get Alerted When PLX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: PLX is fairly priced but lacks strong directional signals. At 11.2% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: PLX is fairly priced but lacks strong directional signals. At 11.2% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: PLX is currently trading at $2.37, which is considered fair relative to its 30-day fair value range of $2.30 to $2.45. From a valuation perspective, the stock is trading at a premium (Forward PE: 43.3) compared to its historical average (31.5). At these levels, the market is pricing in 11.2% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, PLX is in a uptrend. Immediate support is located at $2.17, while resistance sits at $2.71.
Market Sentiment: The stock scores a mixed 56/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (25th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $11.00 (+362.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PLX is in a uptrend. Immediate support is located at $2.17, while resistance sits at $2.71.
Market Sentiment: The stock scores a mixed 56/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (25th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $11.00 (+362.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$2.30 -
$2.45
Company Quality Score
49/100
(HOLD)
Options IV Signal
25th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
77.7%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 25th percentile)
- NEUTRAL: Mixed technical signals (56/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 362.2% below Wall St target ($11.00)
- NEUTRAL: PE elevated vs history but 11.2% growth expectation is conservative given 2241% recent growth
- WARNING: Composite score 49/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$2.30 -
$2.45
Current vs Trading Range
FAIR
Expected Move (7 Days)
Âą$0.32
(13.7%)
Support & Resistance Levels
Support Level
$2.17
Resistance Level
$2.71
Current Trend
Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
43.27
Wall Street Target
$11.00
(+362.2%)
Revenue Growth (YoY)
27.1%
Earnings Growth (YoY)
2241.1%
Profit Margin
23.5%
Valuation Premium vs History
+11.2% premium
PE vs Historical
43.3 vs 31.5
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+11.2%
(market-implied from PE analysis)
1-Year Target
$2.65
(+11%)
2-Year Target
$2.94
(+24%)
3-Year Target
$3.27
(+38%)
3-Yr Target (if PE normalizes)
(PE: 43â32)
PE COMPRESSION
$2.38
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 43.3, Growth: -71.1%)
$1.74
(+-27%)
Base:
(SPY PE: 20.1, Growth: -71.1%)
$0.80
(-66%)
Bear:
(PE: 17.1, Growth: -71.1%)
$0.68
(-71%)
đ
Valuation based on Current Earnings
Trailing PE: 10.35 | Current EPS (TTM): $0.23
Bull Case
$1.31
(-45%)
Analyst growth -50.0%, PE expands to 11.4
Base Case
$1.19
(-50%)
Market implied -50.0%, PE stable at 10.4
Bear Case
$1.62
(-32%)
Severe decline -20.0%, PE contracts to 8.8
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: August 24, 2026 12:55 PM ET
Data refreshes hourly during market hours. Next update: 1:55 PM
Data refreshes hourly during market hours. Next update: 1:55 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PLX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 33 SELL |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1173 | 43 HOLD |
|
REGN
Regeneron PharmaceuticalâĻ |
STRONG BUY
25 analysts |
$840 | 34 SELL |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$281 | 55 HOLD |
|
MLTX
MoonLake ImmunotherapeutâĻ |
STRONG BUY
16 analysts |
$29 | 49 HOLD |
